Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)

Inclusion Criteria

• •Patients with histologic proof of HD who are in relapse and have failed \> or = to 2 prior chemotherapy regimens.
• •Patients must have a life expectancy of at least 8 weeks.
• •All patients must have ECOG performance level rating of \< or = to 2.
• •Patients or their parents (guardian) must sign an informed consent indicating that they are aware of the investigational nature of the study.
• •Patients must have recovered from the toxic effects of prior therapy before entering this study or at least 2 weeks should have elapsed since the end of last course of CT.
• •Patients must have adequate liver function (bilirubin \< or = to 2.0 mg/dl, SGOT less than 1.5 times normal (unless it is due to disease), adequate renal function (creatinine \< or = to 1.5 mg/dl, creatinine clearance \> or = to 60 ml/min/1.73 m2).
• •Patients should have a granulocyte count \> or = to 500/gL and a platelet count \> or = to 100,000/uL (unless due to disease involvement of the bone marrow).
• •Male and female patients of child-bearing age should use effective methods of contraception, if sexually active.